AstraZeneca Forxiga meets primary endpoint for type 2 diabetes
Cambridge: AstraZeneca has announced positive results from the T2NOW Phase III trial, one of the largest paediatric type 2 diabetes studies performed to date. The results from the trial demonstrated significant reduction in A1C, a marker of average blood sugar, for patients treated with Forxiga (dapagliflozin) compared with patients receiving placebo. Adjusted mean change in A1C was −0.62% for Forxiga versus +0.41% for placebo, a difference of −1.03% (95% CI: -1.57-0.49; p<0.001). Statistical significance was achieved in the primary endpoint and in all secondary endpoints versus placebo at week 26, establishing that Forxiga can provide clinically meaningful improvements in glycemia for children and adolescents with type 2 diabetes (T2D). The safety results in this patient population were consistent with those in adults with T2D, in line with the well-established safety profile for Forxiga.
Naim Shehadeh, Professor of Endocrinology, Rambam Health Care Campus, Israel, said, “The significant decrease in A1C that we observed in patients receiving Forxiga may indicate a reduction in the progression of disease and its complications. This is an important treatment consideration as children and adolescents with type 2 diabetes often experience earlier onset of complications and faster advancement of disease compared to adults with the same condition.”
Reference: Naim Shehadeh, Timothy Barrett, Pietro Galassetti, Cecilia Karlsson, Dapagliflozin or Saxagliptin in Pediatric Type 2 Diabetes, DOI: 10.1056/EVIDoa2300210
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.